138 related articles for article (PubMed ID: 36547869)
21. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
22. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Greenup R; Buchanan A; Lorizio W; Rhoads K; Chan S; Leedom T; King R; McLennan J; Crawford B; Kelly Marcom P; Shelley Hwang E
Ann Surg Oncol; 2013 Oct; 20(10):3254-8. PubMed ID: 23975317
[TBL] [Abstract][Full Text] [Related]
24. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
Clark NM; Roberts EA; Fedorenko C; Sun Q; Dubard-Gault M; Handford C; Yung R; Cheng HH; Sham JG; Norquist BM; Flanagan MR
Ann Surg Oncol; 2023 Mar; 30(3):1312-1326. PubMed ID: 36335273
[TBL] [Abstract][Full Text] [Related]
25. The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.
Okano M; Nomizu T; Tachibana K; Nagatsuka M; Matsuzaki M; Katagata N; Ohtake T; Yokoyama S; Arai M; Nakamura S
J Hum Genet; 2021 Mar; 66(3):307-314. PubMed ID: 33046835
[TBL] [Abstract][Full Text] [Related]
26. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
[TBL] [Abstract][Full Text] [Related]
27. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
28. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
29. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
30. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
31. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES
Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489
[TBL] [Abstract][Full Text] [Related]
32. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
33. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Nené NR; Reisel D; Leimbach A; Franchi D; Jones A; Evans I; Knapp S; Ryan A; Ghazali S; Timms JF; Paprotka T; Bjørge L; Zikan M; Cibula D; Colombo N; Widschwendter M
Lancet Oncol; 2019 Aug; 20(8):1171-1182. PubMed ID: 31300207
[TBL] [Abstract][Full Text] [Related]
34. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.
Villarreal-Garza C; Alvarez-Gómez RM; Pérez-Plasencia C; Herrera LA; Herzog J; Castillo D; Mohar A; Castro C; Gallardo LN; Gallardo D; Santibáñez M; Blazer KR; Weitzel JN
Cancer; 2015 Feb; 121(3):372-8. PubMed ID: 25236687
[TBL] [Abstract][Full Text] [Related]
35. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
Kim SH; Hwang HK; Lee WJ; Kang CM
Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442
[TBL] [Abstract][Full Text] [Related]
36. BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.
Chun DS; Berse B; Venne VL; DuVall SL; Filipski KK; Kelley MJ; Meyer LJ; Icardi MS; Lynch JA
Fam Cancer; 2017 Jan; 16(1):41-49. PubMed ID: 27589855
[TBL] [Abstract][Full Text] [Related]
37. Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
Mahtani R; Niyazov A; Lewis K; Rider A; Massey L; Arondekar B; Lux MP
Adv Ther; 2023 Jan; 40(1):331-348. PubMed ID: 36333567
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
Alemar B; Gregório C; Herzog J; Matzenbacher Bittar C; Brinckmann Oliveira Netto C; Artigalas O; Schwartz IVD; Coffa J; Alves Camey S; Weitzel J; Ashton-Prolla P
PLoS One; 2017; 12(11):e0187630. PubMed ID: 29161300
[TBL] [Abstract][Full Text] [Related]
39. The Role of Genetic Testing in Patients With Breast Cancer: A Review.
Valencia OM; Samuel SE; Viscusi RK; Riall TS; Neumayer LA; Aziz H
JAMA Surg; 2017 Jun; 152(6):589-594. PubMed ID: 28423155
[TBL] [Abstract][Full Text] [Related]
40. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]